A Guide to Immunogen Preparation Service for Nanobody Discovery: Antigen Formats, Workflow, and Quality Checks
Immunogen preparation for nanobody discovery is the process of designing, producing, and checking an antigen suitable for camelid immunization and downstream binder screening. The right format depends on the target: a purified protein may suit a soluble enzyme, while a membrane protein, domain complex, or peptide conjugate may be needed to represent a particular epitope. At NBbiolab, we work with clients to align antigen format, project purpose, and quality checks before the material is used. This guide explains the main choices and what to discuss when evaluating a service.
Key Takeaways
- Choose an antigen that represents the form and epitope the intended nanobody must recognize.
- Agree on identity, purity, concentration, buffer, and relevant functional checks before production begins.
- For veterinary projects, consider species-specific sequences, pathogen or host context, and the intended assay or application.
- Ask suppliers to clarify scope, assumptions, sample requirements, storage, timeline, and any project-specific acceptance criteria.
Who This Guide Is For
This guide is for veterinary medicine researchers, biotechnology teams, and procurement or project leads planning nanobody discovery. It is useful whether you already have a purified target or need support selecting and preparing an immunogen. The information can also help teams compare service proposals using consistent technical questions. It is not a substitute for target-specific experimental design or a guarantee of discovery outcomes.
What Immunogen Preparation Involves
An immunogen is material presented to an animal to elicit an immune response against a chosen target. In a nanobody project, the immunogen should expose relevant target features while retaining enough structural or functional similarity to the molecule the final binder is expected to recognize. Nanobodies are commonly described as single-domain antibody fragments with molecular masses of approximately 12–15 kDa, but their discovery depends on the target, immunization strategy, and screening process—not molecular size alone.
Preparation may include construct design, expression, purification, formulation, and analytical checks. The specific scope varies by supplier and project. It is important to distinguish immunogen preparation from the full discovery workflow: supplying antigen does not, by itself, include immunization, library construction, screening, sequencing, or validation unless those activities are explicitly included.
Antigen Formats and Material Options
Recombinant Full-Length Proteins and Domains
Recombinant proteins are often considered for soluble targets, extracellular regions, enzymes, and other proteins that can be produced in an appropriate expression system. A full-length protein can preserve more target context, while a domain construct may be easier to express or focus the immune response on a particular region. Construct boundaries and tags should be reviewed because they can affect folding, solubility, and which epitopes are exposed.
Membrane Proteins and Protein Complexes
For membrane targets, a purified soluble fragment may not reproduce the conformation found in a cell membrane. Options can include extracellular domains, stabilized constructs, detergent or lipid-associated preparations, and cell-based antigen formats. Each option has trade-offs in stability, accessibility, and suitability for downstream screening. If the desired nanobody must bind a native cell-surface target, discuss how the immunogen and screening antigen will represent that native context.
Peptides, Conjugates, and Alternatives
Peptides can be useful when the desired binding site is a defined linear sequence or a short region with a clear application. They may be less suitable when the target epitope depends on three-dimensional folding, post-translational modifications, or interactions with neighboring domains. A peptide may be coupled to a carrier to support immunogenicity, but the carrier and conjugation strategy should be considered during screening to help distinguish target-specific recognition from carrier reactivity.
For some veterinary targets, whole-cell, lysate, or pathogen-associated material may be considered, subject to biosafety, availability, and project requirements. These complex materials can present multiple antigens, so they may require a more carefully defined screening strategy than a purified target.
Matching Antigen Format to Application
Start with the intended use of the nanobody rather than selecting an antigen solely because it is convenient to produce. A reagent for a soluble-protein assay may be discovered using a purified protein, whereas a diagnostic or research reagent intended to recognize native pathogen or host-cell targets may need a screening antigen that reflects those conditions. For veterinary medicine, clarify the relevant animal species, target variant, pathogen strain, and sample type wherever these are known.
Also plan the relationship between immunization and screening. An immunogen can be suitable for eliciting a response yet differ from the antigen used in the final assay. Using complementary formats for immunization and screening may help prioritize binders that recognize the intended target rather than a purification tag or carrier, but the choice should be made based on the project’s goals.
If you want to learn more, please visit our website NBbiolab.
Typical Workflow and Quality Checks
1. Define the Target and Project Requirements
Provide the target name, sequence or accession where available, species, intended application, and known structural or biological constraints. Explain whether the desired binder should recognize a linear region, native conformation, specific domain, or particular variant. These details help the supplier identify construct and format questions before production.
2. Select the Construct and Production Approach
Review construct boundaries, expression system, tags, and any modifications that may matter to the target. The best expression system depends on properties such as folding, disulfide bonds, and post-translational requirements. Ask the supplier to identify assumptions and alternatives, especially if the target is membrane-associated, unstable, or available only in limited quantities.
3. Produce, Purify, and Formulate the Antigen
Production and purification are followed by buffer selection and preparation for shipment or use. A 0.22 µm filtration step may be used when compatible with the material and project, but it is not appropriate for every antigen and does not replace other quality or biosafety assessments. Discuss any carrier, adjuvant, or formulation requirements separately, and confirm which components are included in the service scope.
4. Review Quality Data and Handling Instructions
Request a project-appropriate report covering identity, concentration, purity assessment, and relevant functional or structural checks where feasible. Common methods may include electrophoresis, chromatography, mass spectrometry, or binding and activity assays, but the method should match the question being answered. Purity by itself does not confirm that an antigen retains the epitope or activity needed for the intended application.
Confirm the storage and shipping conditions in writing. For many protein reagents, 4°C may be used for short-term handling and -80°C for longer-term storage, but stability depends on the molecule, buffer, and freeze-thaw history. Follow the supplier’s instructions for the specific preparation rather than treating these temperatures as universal requirements.
How to Evaluate a Service Provider
Compare proposals on technical fit, transparency, and deliverables—not only on the quoted price. Ask whether the quote covers construct design, expression, purification, quality testing, formulation, and shipping, and identify any work that is optional or billed separately. Request a clear description of sample quantity, concentration, buffer, documentation, and criteria for accepting the final material.
Questions to Include in a Supplier Discussion
- Which antigen format and construct do you recommend, and what assumptions inform that recommendation?
- What identity, purity, concentration, and functional checks are included in the deliverables?
- How will tags, carriers, or non-target components be considered during downstream screening?
- What are the estimated lead time, minimum order or sample requirements, and factors that could change them?
- How will the material be packaged, stored, and accompanied by handling instructions?
Pricing, Minimum Requirements, and Lead Time
Cost and timing depend on target complexity, construct design, expression system, scale, purification difficulty, and the analyses requested. A readily expressed soluble protein may involve a different scope from a membrane protein or a complex requiring specialized stabilization. Because providers may define minimum quantities and quality packages differently, request an itemized proposal rather than comparing headline prices alone.
Before placing an order, share the intended discovery schedule and any fixed downstream dates. Ask which milestones are estimates, what material or sequence information is needed to begin, and how delays or production challenges will be communicated. These details make it easier to assess whether a proposed service fits the project plan without relying on generic turnaround claims.
Conclusion: Choose for the Intended Binder, Not Just the Available Antigen
A suitable immunogen is one that supports the intended nanobody discovery goal and can be assessed with quality checks relevant to that goal. Define the target context first, select an antigen format that represents the desired epitope, and confirm how the material will be characterized and handled. For veterinary projects, include species, variant, and application details early so they can inform both antigen selection and downstream screening.
NBbiolab can discuss immunogen format, preparation scope, and quality documentation for your nanobody discovery project. To request a project assessment, share the target information, intended application, preferred schedule, and any existing antigen data; we can then help identify the details to resolve before quotation and production.